Cumberland Pharmaceuticals Hits New 52-Week High of $8.45

Cumberland Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 8.45 on August 10, 2026. This achievement marks a remarkable increase in the stock's performance, reflecting a 448.59% rise over the past year, significantly outpacing the S&P 500's performance of 21.34% during the same period. As a microcap company in the Pharmaceuticals & Biotechnology industry, Cumberland Pharmaceuticals has a market capitalization of USD 46 million. Despite being in a loss-making position, the stock's recent performance highlights its potential within the sector. The company's price-to-book ratio stands at 1.85, indicating how the market values its assets relative to its stock price. With a debt-to-equity ratio of -0.23 and a return on equity of -11.00%, Cumberland Pharmaceuticals continues to navigate its financial landscape. The stock's previous 52-week low was recorded at USD 1.85, showcasing the significant growth it has experienced in the past year. This upward trend in stock price underscores the dynamic nature of the pharmaceutical market.